982 related articles for article (PubMed ID: 18927529)
1. Is there a place for postmenopausal hormone therapy use in women with lupus?
Gompel A; Piette JC
Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
[TBL] [Abstract][Full Text] [Related]
2. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
Harman SM; Naftolin F; Brinton EA; Judelson DR
Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
[TBL] [Abstract][Full Text] [Related]
3. Menopause and stroke and the effects of hormonal therapy.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus and hormone replacement therapy.
Gompel A; Piette JC
Menopause Int; 2007 Jun; 13(2):65-70. PubMed ID: 17540136
[TBL] [Abstract][Full Text] [Related]
6. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
7. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
8. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
9. A comparative review of the risks and benefits of hormone replacement therapy regimens.
Warren MP
Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
[TBL] [Abstract][Full Text] [Related]
10. Indications for hormone therapy: the post-Women's Health Initiative era.
Reed SD; Newton KM; Lacroix AZ
Endocrinol Metab Clin North Am; 2004 Dec; 33(4):691-715. PubMed ID: 15501641
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
[TBL] [Abstract][Full Text] [Related]
12. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
Banks E; Canfell K
Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hormone therapy: from monkey glands to transdermal patches.
Davis SR; Dinatale I; Rivera-Woll L; Davison S
J Endocrinol; 2005 May; 185(2):207-22. PubMed ID: 15845914
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
[TBL] [Abstract][Full Text] [Related]
15. WHI risks: any relevance to menopause management?
Burger HG
Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
[TBL] [Abstract][Full Text] [Related]
16. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
Brinton RD
Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
Salpeter S
Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
[TBL] [Abstract][Full Text] [Related]
18. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
Shulman LP
J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
[No Abstract] [Full Text] [Related]
19. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
La Vecchia C
Breast; 2004 Dec; 13(6):515-8. PubMed ID: 15563861
[TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
van de Weijer PH; Mattsson LA; Ylikorkala O
Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
